# Hanmi's Obesity Drug Epe Sells Out in Record Time [K-Bio Pulse]

> Hanmi Pharmaceutical shares rose more than 6% on November 20 after reports that the initial supply of its domestically developed obesity drug Epe, worth about KRW 10 billion, sold out ahead of expectations. The gain came during a sharp broader sell-off in which the KOSPI and KOSDAQ fell more than 5% intraday.

- Date: 2026-11-21 · published 2026-11-22T00:15:57.771Z
- Category: market · region South Korea · magnitude low
- Page: https://feedsoft.ai/events/113606-hanmi-s-obesity-drug-epe-sells-out-in-record-time-k-bio-pulse
- Commodities: [Methionine Hydroxy Analogue](https://feedsoft.ai/c/MHA.md)

## Why it matters

This is a pharmaceutical equity story with no direct link to feed grains, oilseeds, or animal-feed ingredient supply or prices.

## Sources

- en.edaily.co.kr: https://en.edaily.co.kr/news/eda202611225030/

---
Data from Feedsoft AI (https://feedsoft.ai/). For information only; not investment advice.
